Daily Newsletter

07 September 2023

Daily Newsletter

07 September 2023

Boston Scientific’s LAAC device gets FDA approval

The new device is being evaluated in the single-centre premarket WATCHMAN FLX Pro CT study.

RanjithKumar Dharma September 07 2023

Boston Scientific has received approval from the US Food and Drug Administration (FDA) for its WATCHMAN FLX Pro left atrial appendage closure (LAAC) device.

The latest-generation device leverages the established safety and procedural performance of the WATCHMAN FLX LAAC device, which received approval in July 2020.

It features an advanced coating designed to lower device-related thrombosis while promoting rapid, controlled healing and endothelisation of the device surface.

The device also has visualisation markers, which help advance device placement for optimal sealing around the LAA.

The company offers a new 40mm option for the device, helping physicians treat a wide range of anatomies with WATCHMAN technology.

Meanwhile, the new device is being assessed in the single-centre premarket WATCHMAN FLX Pro CT study.

The study utilises multiple imaging modalities for evaluating device tissue coverage after the procedure and its potential connection to clinical outcomes.

The device will undergo additional assessment in the post-market HEAL-LAA study, set to begin in the next few weeks.

This study will monitor the results of approximately 1,000 patients with NVAF who have received the technology at 60 different sites in the US.

Boston Scientific Cardiology group president Joe Fitzgerald said: “We are pleased to introduce US clinicians to our newest LAAC technology, which is designed to enhance post-procedural healing, improve the precision of WATCHMAN FLX Pro implants and expand the size range of treatable appendages.

“These enhancements to our WATCHMAN FLX technology will enable efficiency during implant procedures and allow physicians to optimise treatment for their patients.”

Medical robotics set to witness robust growth in the next decade

GlobalData expects every segment of the medical robotics market to grow over the next decade, driven by the demands of high-volume procedures. Per GlobalData forecasts, the surgical robotics market is expected to grow at a CAGR of 8% by 2030. Surgical robots improve patient outcomes, reduce human error, and decrease the length of hospital stays. New surgical robot models will offer new surgical possibilities, such as micro-robots to address difficult-to-treat diseases.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close